£22.5M
The Series A round was backed by Syncona Investment Management and Cambridge Innovation Capital to support pipeline progression and team expansion.
Mosaic Therapeutics
Mosaic Therapeutics develops targeted oncology treatments using advanced computational methods and cancer genomics.
£22.5MTotal raised
Mosaic Therapeutics develops targeted oncology therapies by combining advanced computational methods with next-generation cancer models. The firm builds upon research originating from the Wellcome Sanger Institute and the Netherlands Cancer Institute.
Categories
Founders
Mathew Garnett
Senior Group Leader
Mathew brings biotech entrepreneurial and research experience from the Wellcome Sanger Institute, the University of Cambridge, and Mosaic Therapeutics.
LinkedIn
Emile Voest
Professor of Medical Oncology
Emile brings extensive oncology and life sciences experience, holding professorships and senior roles at The Netherlands Cancer Institute, UMC Utrecht, and the Oncode Institute. He also contributes governance and advisory expertise as a board member at Sanofi and through founding several medical organisations including Mosaic Therapeutics.
LinkedIn
Adrian Ibrahim
Head of Technology Translation
Adrian brings executive and founding experience across life sciences innovation, biopharma, and deeptech companies. He currently serves as an entrepreneur in residence and chief executive officer.
LinkedIn